Object's details: GLP-1 Receptor Agonists: Therapeutic Benefits in Renal Function, Cardiovascular Risk, and Physical Activity - A Systematic Review

Provider:Akademicka Platforma Czasopism

Description

Title:
GLP-1 Receptor Agonists: Therapeutic Benefits in Renal Function, Cardiovascular Risk, and Physical Activity - A Systematic Review
Creator:
Karaban, grzegorz;
Kuźnieców, Tadeusz;
Paszkowska, Monika;
Mularczyk, Klaudia;
Borawski, Michał;
Ciuła, Aleksandra;
Jakubiak, Anna;
Miśkiewicz, Joanna;
Znamirowska, Patrycja;
Kupis, Magdalena
Description:
Introduction: Type 2 diabetes is one of the greatest challenges of modern medicine. Its growing prevalence and numerous complications, especially cardiovascular ones, demand constant improvement of treatment strategies. Cardiovascular disease remains the leading cause of death in these patients, highlighting the importance of therapies that address both glycaemic control and cardiovascular risk. Aim of the study: This paper discusses the effects of GLP-1 receptor agonists (GLP-1 RA) and analyses recent data on their impact on cardiovascular risk, renal function, and interaction with physical activity. Key clinical trials and practical applications in daily practice are also presented. State of knowledge: GLP-1 RAs are well-established in the treatment of type 2 diabetes and obesity. They effectively lower glucose levels and reduce body weight while offering cardiovascular and nephroprotective benefits. Their role is particularly significant in patients with chronic kidney disease. Emerging data also suggest possible applications beyond diabetology, including neurology and cardiology. Material and methods: A PubMed search was conducted using relevant keywords for studies available up to March 2025. Only English-language publications were included. After title and abstract screening, full texts of eligible articles were analysed. Conclusions: GLP-1 RAs are a valuable part of therapy for patients with type 2 diabetes and obesity. They improve glycaemic control, support weight loss, and reduce cardiovascular and renal risk. Their safety profile allows for combination with other drugs. When used alongside physical activity, they can significantly enhance health outcomes and quality of life.
Object availability:
free access
Rights: https://creativecommons.org/licenses/by-nc-sa/4.0 ;
Prawa autorskie (c) 2025 Łukasz Karaban, Tadeusz Kuźnieców, Monika Paszkowska, Klaudia Mularczyk, Michał Borawski, Aleksandra Ciuła, Anna Jakubiak, Joanna Miśkiewicz, Patrycja Znamirowska, Magdalena Kupis
Date:
2025.05.09
Type:
info:eu-repo/semantics/article;
info:eu-repo/semantics/publishedVersion
Language:
English
Source:
Quality in Sport; Tom 41 (2025); 60343;
Quality in Sport; Vol. 41 (2025); 60343;
2450-3118
Format:
application/pdf
Publisher:
University Center for Sports Research, Nicolaus Copernicus University, Torun, Poland
Relation: https://apcz.umk.pl/QS/article/view/60343/42441
Subject:
GLP-1 RA;
semaglutide;
type 2 diabetes;
cardiovascular risk;
macroalbuminuria
Identifier: https://apcz.umk.pl/QS/article/view/60343
Data provider:
Akademicka Platforma Czasopism

Similar objects

GLP-1 Receptor Agonists: Therapeutic Benefits in Renal Function, Cardiovascular Risk, and Physical Activity - A Systematic Review

Date:2025.05.09

Type:text

The role of flozins in managing cardiovascular risk in patients with type 2 diabetes - narrative review

Date:2024.09.30

Type:text

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes

Date:2024.12.16

Type:text

Pioglitazone - the forgotten drug with multidirectional action

Creator:Aab, Arkadiusz | Zarańska, Julia

Date:2023.04.25

Type:text

Pathophysiological association of expression hormone of adipose tissue omentin-1 and the degree of vascular remodeling of brachyocephalic vessels in persons with obesity and disorders of carbohydrate metabolism

Creator:Kulynych, Roman Leonidovich | Soloviuk, Olena Anatolyevna | Soloviuk, Oleksandr Olegovich

Date:2020.10.30

Type:text

Potential of GLP-1 Analogs in Managing Hyperphagia and Obesity in Prader-Willi Syndrome: A Review of Efficacy and Safety

Date:2024.10.14

Type:text

Hypoglycemia, Arrythmia and Mortality in Diabetes, an underestimated risk?

Date:2025.06.19

Type:text

Correlation between muscle tissue and type 2 diabetes

Date:2024.08.12

Type:text

Federacja Bibliotek Cyfrowych

Object's details: GLP-1 Receptor Agonists: Therapeutic Benefits in Renal Function, Cardiovascular Risk, and Physical Activity - A Systematic Review

Description

Similar objects